C4 Therapeutics (CCCC) FCF Margin (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly FCF Margin of 487.35% in Q1 2026, down 142.31% quarter-over-quarter from 201.13% in Q4 2025, and down 2749.0% on a YoY basis from 18.4% in Q1 2025.
C4 Therapeutics (CCCC) FCF Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' FCF Margin history runs 8 years deep, the most recent figure standing at 487.35% for Q1 2026.
- In Q1 2026, FCF Margin fell 2749.0% year-over-year to 487.35%; the TTM figure through Mar 2026 stood at 275.37% (down 7302.0% YoY), while the FY2025 annual figure was 276.24%, down 9263.0% from the prior year.
- FCF Margin was 487.35% for Q1 2026 at C4 Therapeutics, down from 201.13% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 41.54% in Q2 2024 to a low of 986.19% in Q4 2022.
- Historically, FCF Margin has averaged 426.36% across 5 years, with a median of 349.73% in 2022.
- The sharpest annual moves came in 2022 and 2024: FCF Margin tumbled 85780 bps in 2022, then soared 67258 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 986.19% in 2022, then jumped by 30 bps to 689.24% in 2023, then surged by 50 bps to 346.3% in 2024, then jumped by 42 bps to 201.13% in 2025, then slumped by 142 bps to 487.35% in 2026.
- The last three FCF Margin figures came in at 487.35% (Q1 2026), 201.13% (Q4 2025), and 280.58% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -487.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -487.35% |
| Dec 31, 2025 | -201.13% |
| Sep 30, 2025 | -280.58% |
| Jun 30, 2025 | -191.10% |
| Mar 31, 2025 | -459.86% |
| Dec 31, 2024 | -346.30% |
| Sep 30, 2024 | -158.21% |
| Jun 30, 2024 | -41.54% |
| Mar 31, 2024 | -596.18% |
| Dec 31, 2023 | -689.24% |
| Sep 30, 2023 | -289.33% |
| Jun 30, 2023 | -714.11% |
| Mar 31, 2023 | -886.43% |
| Dec 31, 2022 | -986.19% |
| Sep 30, 2022 | -387.99% |
| Jun 30, 2022 | -182.83% |
| Mar 31, 2022 | -349.73% |
| Dec 31, 2021 | -128.40% |
| Sep 30, 2021 | -215.98% |
| Jun 30, 2021 | -191.69% |